ADMP - Adamis pharmaceuticals gets deficiency letter from NASDAQ

Adamis Pharmaceuticals (ADMP) has received a notification letter from the Nasdaq Stock Market notifying the company that it is not in compliance with the exchange's listing requirements after failing to file its quarterly report on Form 10-Q on time.The notice also indicated that the company has 60 calendar days to submit a plan to regain compliance and, if NASDAQ accepts the plan, it can grant an exception of up to 180 calendar days from the filing’s due date to regain compliance.The notice has no immediate effect on the listing of the company’s shares on the exchange.

For further details see:

Adamis pharmaceuticals gets deficiency letter from NASDAQ